Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.12 USD
-0.02 (-0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.13 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TBPH 9.12 -0.02(-0.22%)
Will TBPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Other News for TBPH
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Theravance Biopharma Breaks Above 200-Day Moving Average - Bullish for TBPH
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Theravance Biopharma initiated with bullish view at BTIG, here's why
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024